You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Discontinued Product(S)-α-Methyl-3-carboxyphenylalanine (Cat. No. 0857) has been withdrawn from sale for commercial reasons.
Biological Activity for (S)-α-Methyl-3-carboxyphenylalanine
Potent, highly selective antagonist of L-AP4- induced depression of forskolin-stimulated cAMP production in rat brain cerebrocortical slices; 100 fold less potent versus L-CCG-I -induced depression.
Technical Data for (S)-α-Methyl-3-carboxyphenylalanine
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for (S)-α-Methyl-3-carboxyphenylalanine
References for (S)-α-Methyl-3-carboxyphenylalanine
References are publications that support the biological activity of the product.
Bruno et al (1996) Activation of group III metabotropic glutamate receptors is neuroprotective in cortical cultures. Eur.J.Pharmacol. 310 61 PMID: 8880068
Sekiyama et al (1996) Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes. Br.J.Pharmacol. 117 1493 PMID: 8730745
Watkins and Collingridge (1994) Phenylglycine derivatives as antagonists of metabotropic glutamate receptors. TiPS 15 333 PMID: 7992387
Kemp et al (1994) Antagonist effects of 3-carboxy derivatives of phenylglycine and phenylalanine mGluR ligands on cortical adenylyl cyclase activity. Br.J.Pharmacol. 113 147P
View Related Products by Target
View Related Products by Product Action
Keywords: (S)-a-Methyl-3-carboxyphenylalanine, (S)-a-Methyl-3-carboxyphenylalanine supplier, Glutamate, (Metabotropic), Group, III, Receptors, 0857, Tocris Bioscience
Citations for (S)-α-Methyl-3-carboxyphenylalanine
Citations are publications that use Tocris products.
Currently there are no citations for (S)-α-Methyl-3-carboxyphenylalanine.
Reviews for (S)-α-Methyl-3-carboxyphenylalanine
There are currently no reviews for this product. Be the first to review (S)-α-Methyl-3-carboxyphenylalanine and earn rewards!
Have you used (S)-α-Methyl-3-carboxyphenylalanine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.